These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 19126937)

  • 1. Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension.
    Bharani A; Patel A; Saraf J; Jain A; Mehrotra S; Lunia B
    Indian Heart J; 2007; 59(4):323-8. PubMed ID: 19126937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension.
    Bharani A; Mathew V; Sahu A; Lunia B
    Indian Heart J; 2003; 55(1):55-9. PubMed ID: 12760589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension.
    Singh TP; Rohit M; Grover A; Malhotra S; Vijayvergiya R
    Am Heart J; 2006 Apr; 151(4):851.e1-5. PubMed ID: 16569546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension.
    Pepke-Zaba J; Beardsworth A; Chan M; Angalakuditi M
    Curr Med Res Opin; 2009 Oct; 25(10):2479-85. PubMed ID: 19686085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship.
    Garg N; Sharma MK; Sinha N
    Int J Cardiol; 2007 Sep; 120(3):306-13. PubMed ID: 17174417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome--a randomized, placebo-controlled, double-blind crossover study.
    Mukhopadhyay S; Nathani S; Yusuf J; Shrimal D; Tyagi S
    Congenit Heart Dis; 2011; 6(5):424-31. PubMed ID: 21914136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: a pilot study.
    Bendayan D; Shitrit D; Kramer MR
    Respirology; 2008 Nov; 13(6):916-8. PubMed ID: 18811891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension.
    Arif SA; Poon H
    Clin Ther; 2011 Aug; 33(8):993-1004. PubMed ID: 21762988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tadalafil for the treatment of pulmonary arterial hypertension.
    Rosenzweig EB
    Expert Opin Pharmacother; 2010 Jan; 11(1):127-32. PubMed ID: 20001434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral tadalafil in pulmonary artery hypertension: a prospective study.
    Aggarwal P; Patial RK; Negi PC; Marwaha R
    Indian Heart J; 2007; 59(4):329-35. PubMed ID: 19126938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study.
    Mukhopadhyay S; Sharma M; Ramakrishnan S; Yusuf J; Gupta MD; Bhamri N; Trehan V; Tyagi S
    Circulation; 2006 Oct; 114(17):1807-10. PubMed ID: 17030688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study.
    Oudiz RJ; Brundage BH; Galiè N; Ghofrani HA; Simonneau G; Botros FT; Chan M; Beardsworth A; Barst RJ;
    J Am Coll Cardiol; 2012 Aug; 60(8):768-74. PubMed ID: 22818063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease.
    Badesch DB; Hill NS; Burgess G; Rubin LJ; Barst RJ; Galiè N; Simonneau G;
    J Rheumatol; 2007 Dec; 34(12):2417-22. PubMed ID: 17985403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension].
    Sakuma M; Shirato K
    Nihon Rinsho; 2008 Nov; 66(11):2157-61. PubMed ID: 19051736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sildenafil therapy for pulmonary arterial hypertension associated with atrial septal defects.
    Lim ZS; Salmon AP; Vettukattil JJ; Veldtman GR
    Int J Cardiol; 2007 May; 118(2):178-82. PubMed ID: 17027100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
    Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
    J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of oral tadalafil, a new long-acting phosphodiesterase-5 inhibitor, for the short-term treatment of pulmonary arterial hypertension in a dog.
    Serres F; Nicolle AP; Tissier R; Gouni V; Pouchelon JL; Chetboul V
    J Vet Med A Physiol Pathol Clin Med; 2006 Apr; 53(3):129-33. PubMed ID: 16533328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension.
    Shapiro S; Traiger G; Hill W; Zhang L; Doran AK
    Cardiovasc Ther; 2013 Oct; 31(5):274-9. PubMed ID: 23841794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of tadalafil in men with erectile dysfunction following spinal cord injury.
    Giuliano F; Sanchez-Ramos A; Löchner-Ernst D; Del Popolo G; Cruz N; Leriche A; Lombardi G; Reichert S; Dahl P; Elion-Mboussa A; Casariego J
    Arch Neurol; 2007 Nov; 64(11):1584-92. PubMed ID: 17846260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tadalafil therapy for pulmonary arterial hypertension.
    Galiè N; Brundage BH; Ghofrani HA; Oudiz RJ; Simonneau G; Safdar Z; Shapiro S; White RJ; Chan M; Beardsworth A; Frumkin L; Barst RJ;
    Circulation; 2009 Jun; 119(22):2894-903. PubMed ID: 19470885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.